Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.48 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
| ▸ | FNTB | P49356 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697004 | 1.00 | MAOB (0.61) | MAOBMEN1KMT2AMAPTNPC1 | |
| SCHEMBL4699493 | 0.82 | MAOB (0.65) | MAOBMEN1KMT2AMAPTGAA | |
| SCHEMBL4699500 | 0.82 | MAOB (0.65) | MAOBMEN1KMT2AMAPTGAA | |
| SCHEMBL14035601 | 0.81 | CYP19A1 (0.45) | MAOBMEN1KMT2AMAPTNPC1 | |
| SCHEMBL7269575 | 0.81 | MAOB (0.60) | MAOBMEN1KMT2AMAPTNPC1 | |
| SCHEMBL7269573 | 0.81 | MAOB (0.60) | MAOBMEN1KMT2AMAPTNPC1 | |
| SCHEMBL4696465 | 0.81 | MAOB (0.55) | MAOBMEN1KMT2AMAPTGAA | |
| SCHEMBL4696463 | 0.81 | MAOB (0.55) | MAOBMEN1KMT2AMAPTGAA | |
| SCHEMBL13956250 | 0.81 | MAOB (0.58) | MAOBMAPTLMNA | |
| SCHEMBL4701157 | 0.79 | MAPT (0.59) | MAOBMEN1KMT2AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080274947-A1 | Hydroxy-Substituted Diphenylazetidinones for the Treatment of Hyperlipidemia | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
| US-20080274947-A1 | Hydroxy-Substituted Diphenylazetidinones for the Treatment of Hyperlipidemia | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
| EP-1954673-A1 | HYDROXY-SUBSTITUTED DIPHENYLAZETIDINONES FOR THE TREATMENT OF HYPERLIPIDAEMIA | Sanofi-Aventis Deutschland GmbH (DE) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007059871-A1 | HYDROXY-SUBSTITUTED DIPHENYLAZETIDINONES FOR THE TREATMENT OF HYPERLIPIDAEMIA | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080274947-A1 | Hydroxy-Substituted Diphenylazetidinones for the Treatment of Hyperlipidemia | CYP46A1, GPR119, DHCR7 | MAOB 2097/4885MEN1 2003/4885KMT2A 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.